AstraZeneca/Targacept's TC-5214 Will Become Decision Resources' Proprietary Clinical Gold Standard In 2013 Through 2018 For Treatment Resistant Depression
Advertisement
Surveyed U.S. and European Physicians Indicate that Effect on Depressive Symptoms is the Most Important Drug Attribute They Consider When Prescribing for the Disorder, According to a New Report from Decision Resources